Status:
COMPLETED
Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application
Lead Sponsor:
Galderma R&D
Conditions:
Rosacea
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.
Detailed Description
This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application as measured by the Corneometer CM 82...
Eligibility Criteria
Inclusion
- Clinical diagnosis of moderate to severe rosacea, defined as the presence of at least moderate erythema with telangiectasia and a minimum of two inflammatory lesions
Exclusion
- Individuals with active symptoms of allergy (mild active seasonal allergies are acceptable) or atopic dermatitis
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00436527
Start Date
August 1 2006
End Date
August 1 2006
Last Update
July 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Colorado Springs Research Center
Colorado Springs, Colorado, United States, 80915